Naloxone Hydrochloride (naloxone) is a medication indicated for the reversal of opioid overdose in the event of a drug overdose that is the result of consumption or use of either legally prescribed opioids or from illegal opioids such as heroin.

I. Purpose

This standing order authorizes pharmacists who maintain a current active license practicing in a pharmacy located in South Dakota to initiate a prescription and dispense a naloxone opioid antagonist. This standing order is intended to ensure that naloxone may be readily obtainable by any person (“eligible recipient”) who is:

a) An individual at risk of an opioid-related overdose; or

b) A family member, friend, or other close third party to a person at risk of experiencing an opioid-related overdose.

II. Authority

This standing order is issued pursuant to South Dakota Codified Law (SDCL) § 34-20A-104 which permits that a person who is a family member, friend, or close third party to a person at risk for an opioid-related drug overdose may be prescribed, possess, distribute, or administer an opioid antagonist that is prescribed, dispensed, or distributed by a licensed health care professional directly or by standing order; and § 34-20A-105 which permits a licensed health care professional to directly or by standing order, prescribe an opioid antagonist to a person at risk of experiencing an opioid-related overdose, or prescribe to a family member, friend, or other close third party the health care practitioner reasonably believes to be in a position to assist a person at risk of experiencing an opioid-related overdose.

III. Authorization

This standing order may be used as a prescription to obtain naloxone. This order is authorization for a pharmacist to dispense naloxone and devices for its administration solely in the forms prescribed herein.

IV. Order to Dispense

The pharmacist must utilize the assessment form provided by the South Dakota Board of Pharmacy, found at www.AvoidOpioidSD.com/pharmacy. Upon satisfactory assessment that the person to receive naloxone is an eligible recipient pursuant to this standing order, and upon delivery of basic instruction and information on how to recognize and respond to a possible opioid overdose and how to administer naloxone, the pharmacist shall determine the appropriate product to be dispensed.

a) Intra nasal naloxone spray kits must contain a minimum of the following:

- One (1) FDA-approved naloxone hydrochloride prepackaged kit containing two (2) doses, such as Narcan® Nasal Spray 4mg/0.1mL.

- Step-by-step instructions for administration of intranasal naloxone including a possible second dose, along with basic instructions on calling 911, providing rescue breathing, and monitoring the overdose victim until professional help arrives.
b) Intramuscular naloxone kits must contain a minimum of the following:
   - Two (2) single-use 1 ml vials of naloxone hydrochloride (0.4mg/ml) with syringes and needles.
   - Two (2) single use naloxone hydrochloride 2mg/2ml syringes with needles for IV, IM or SC use.
   - Step-by-step instructions for administration of intramuscular naloxone including a possible second
dose, along with basic instructions on calling 911, providing rescue breathing, and monitoring the
overdose victim until professional help arrives.

c) Intramuscular auto-injector naloxone kits must contain a minimum of the following:
   - One (1) FDA-approved naloxone hydrochloride prepackaged kit containing two (2) doses, such as
     Evzio® or naloxone hydrochloride 2mg/0.4ml autoinjectors.
   - Step-by-step instructions for administration of intramuscular naloxone including a possible second
dose, along with basic instruction on calling 911, providing rescue breathing, and monitoring the
overdose victim until professional help arrives.

V. Standing order compliance requirements

Pharmacists utilizing this standing order to dispense naloxone products must:

a) Maintain a copy of the standing order at the pharmacy.

b) Comply with all South Dakota Board of Pharmacy requirements for prescription orders, labeling,
   recordkeeping, and counseling.

c) Pharmacies choosing to participate in Naloxone dispensing under the authority of this standing order
   must provide notification by completing the form at: www.AvoidOpioidSD.com/pharmacy/participating-pharmacies.

d) Complete at least one hour of training related to naloxone dispensing, administration and recipient
   education.

e) Educate the patient and distribute the patient education materials at the time of dispensing. Education
   materials can be viewed and requested at no cost at: www.AvoidOpioidSD.com/pharmacy.

VI. Record keeping and reporting

a) Pharmacists must maintain dispensing records according to SDCL 36-11-2.2 (3) and 36-11-68
   requirements.

b) Each pharmacy must maintain the original record of each assessment, regardless of the eligibility
determination following the assessment, and dispensing of naloxone to each eligible recipient. These
records shall be available for inspection or copying by the board of pharmacy or its authorized agent for
at least two (2) years from the date of the assessment.

c) Pharmacists must report quarterly for all naloxone dispensed through the statewide standing order.
   Reporting periods and due dates are as follows:

   Reporting period October 1 – December 31 Due: January 31
   Reporting period January 1 – March 31 Due: April 30
   Reporting period April 1 – June 30 Due: July 31
   Reporting period July 1 – September 30 Due: October 31

   Quarterly reports are submitted via: www.AvoidOpioidSD.com/pharmacy/quarterly-reports

VII. Labeling

A prescription label shall be affixed to the naloxone product as required by SDCL 36-11-46.6. The prescription
shall be dispensed in the name of the eligible recipient.
VIII. **Expiration and review**

This standing order will automatically expire two years from the date of authorization, or the date naloxone may be approved as an over-the-counter medication, whichever occurs first. It may be reissued or revoked at the discretion of the signing medical provider. This standing order will be reviewed, and may be updated, if there is relevant new information about naloxone administration.

Mary Carpenter, MD  
10/01/2020  
Mary S. Carpenter, MD  
Date

This standing order is valid for two years from signature date.